Global Oncolytic Virus Therapy Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.

Scope of the Report:
Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
The application of oncolytic virus therapy includes melanoma, prostate cancer, breast cancer, ovarian cancer and others, and the proportion of R&D Investment for melanoma in 2017 is about 34%.
Market competition is intense. Amgen, Oncolytics Biotech, Viralytics, Transgene SA are the leading developers in the industry; with high investment in research marketing and they will monopoly position in the industry.
The global Oncolytic Virus Therapy market is valued at 2 million USD in 2018 and is expected to reach 10 million USD by the end of 2024, growing at a CAGR of 25.8% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Oncolytic Virus Therapy.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Oncolytic Virus Therapy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Oncolytic Virus Therapy market by product type and applications/end industries.

Market Segment by Companies, this report covers
Amgen
Oncolytics Biotech
Viralytics
Transgene SA
Oncolys BioPharma
Targovax
PsiOxus Therapeutics
SillaJen Biotherapeutics
Sorrento Therapeutics
Lokon Pharma
Genelux Corporation
Vyriad
TILT Biotherapeutics
Cold Genesys

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
HSV-based Oncolytic Viruses
Adenoviruses-based Oncolytic Viruses
Vaccinia Virus-based Oncolytic Viruses
Vesicular Stomatitis Virus-based Oncolytic Viruses
Newcastle Disease Virus-based Oncolytic Viruses

Market Segment by Applications, can be divided into
Melanoma
Prostate Cancer
Breast Cancer
Ovarian Cancer 
Others